CC
NVET

CQS Cayman’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

CQS Cayman’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,400
Closed -$111K – 192
2015
Q3 		$111K Hold
30,400
– – 0.01% 151
2015
Q2 		$151K Sell
30,400
-4,600
-13% -$31.9K 0.01% 174
2015
Q1 		$281K Buy
+35,000
New +$331K 0.01% 202

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

CQS Cayman's NVET Position: Q4 2015 in Review

CQS Cayman sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q4 2015, closing a stake of 30,400 shares — an estimated $111K sold.

CQS Cayman first reported a position in NVET in Q1 2015 and held it in 3 quarters. The position peaked at $281K in Q1 2015. 20 funds tracked by Wall St. Rank hold NVET as of Q4 2015.

  • CQS Cayman reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • CQS Cayman sold 30,400 Nexvet Biopharma plc Ordinary Shares shares in Q4 2015, an estimated $111K.
  • CQS Cayman first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 3 quarters.
  • CQS Cayman's Nexvet Biopharma plc Ordinary Shares position peaked at $281K in Q1 2015.
  • 20 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q4 2015.

Based on CQS Cayman's 13F filing for Q4 2015, filed 11 Feb 2016.